

**IN THE UNITED STATES DISTRICT COURT  
FOR THE NORTHERN DISTRICT OF ILLINOIS  
EASTERN DIVISION**

In re: TESTOSTERONE	)	
REPLACEMENT THERAPY	)	Case No. 1:14-cv-01748
PRODUCTS LIABILITY LITIGATION	)	MDL No. 2545
	)	
This Document Relates To:	)	
<i>Cases Identified on Exhibit A</i>	)	
	)	

**DEFENDANTS' FIRST CORRECTED NOTICE OF DEFICIENCY  
PURSUANT TO CASE MANAGEMENT ORDER NO. 115**

Pursuant to Case Management Order No. 115 (Cut-off Date for Supplemental Plaintiff Profile Form With Respect to AbbVie Defendants) (“CMO 115”) (ECF No. 2519), Defendants AbbVie Inc.<sup>1</sup> and Abbott Laboratories (“AbbVie”), by their undersigned counsel, hereby notify the Court of the corrected first group of Plaintiffs who have provided deficient Plaintiff Profile Forms (“PPF”), and in support thereof state as follows:

1. On April 27, 2018, this Court entered CMO 115, directing each Plaintiff asserting claims against AbbVie and subject to Case Management Order No. 85’s (Supplemental Plaintiff Profile Form – PPF) (ECF No. 2295) requirement to submit a PPF with supporting evidence “to ensure that they have submitted a PPF and required medical and pharmacy records that are substantially complete in all respects in compliance with CMO 85.” (CMO 115 at 2)

2. CMO 115 further provides that, after May 11, 2018, “AbbVie shall notify the Court on a rolling basis of any Plaintiffs they believe have continuing deficiencies.” (*Id.*)

---

<sup>1</sup> AbbVie was established in January 2013 as an independent, publicly traded company from the innovative pharmaceutical business of codefendant Abbott Laboratories, which no longer sells AndroGel in the United States.

3. Plaintiffs' counsel are to have 3 business days to meet and confer with AbbVie if they believe they have complied with CMO 115. (*Id.*)

4. AbbVie shall then submit either a "Corrected" or a "Confirmed" Notice of Deficiency, and the Court shall issue an "Order To Show Cause Why the Failure to Comply By May 11, 2018 Should Be Excused." (*Id.*)

5. Plaintiffs' counsel are to have 3 business days to respond to the Order To Show Cause. (*Id.*)

6. On May 16, 2018, AbbVie filed its First Notice of Deficiency Pursuant to CMO 115 ("First Notice") (ECF No. 2630), which identified 374 Plaintiffs who had submitted deficient PPFs.

7. After meeting and conferring with counsel in the days that followed, AbbVie has amended its Notice and submits 169 Plaintiffs on the attached Exhibit A who are all subject to CMO 115 and have continuing deficiencies as outlined in the exhibit. Exhibit A also contains a column listing the outcome of the parties' discussions from the meet-and-confer period.

8. Of the 169 Plaintiffs on the attached Exhibit A, 3 Plaintiffs are considering dismissal but have not yet entered a stipulation of dismissal; 1 Plaintiff has a Motion to Withdraw pending; 53 Plaintiffs have not responded; and 112 Plaintiffs have responded but have not cured their deficiencies.

9. Of the 205 Plaintiffs removed from the First Notice, 11 Plaintiffs have dismissed their cases and 194 Plaintiffs have resolved their deficiencies by either amending their PPFs, providing additional records, or clarifying that they have produced all available records and are relying on the currently produced set of records to substantiate their alleged injuries and AndroGel use. However, while some Plaintiffs may have cured their PPF deficiencies at this stage under

CMO 115, AbbVie reserves the right to challenge lack of product usage in temporal proximity to Plaintiffs' alleged injuries at a later date.

10. AbbVie continues to review the PPFs and supporting records received and anticipates filing additional Deficiency Notices.

**WHEREFORE**, AbbVie respectfully requests that the Court enter an Order To Show Cause Why the Failure to Comply by May 11, 2018 Should Be Excused with respect to the cases on Exhibit A.

Dated: May 25, 2018

/s/ Michelle H. Yeary

Michelle Hart Yeary

DECHERT LLP

A Pennsylvania Limited Liability Partnership

2<sup>nd</sup> Floor, 100 Overlook Center

Princeton, NJ 08540

Telephone: (609) 955-3200

Fax: (609) 955-3259

michelle.yeary@dechert.com

*Attorneys for Defendants AbbVie Inc., and  
Abbott Laboratories, Inc.*

**CERTIFICATE OF SERVICE**

I, Michelle Yeary, hereby certify that on May 25, 2018, the foregoing was filed via the Court's CM/ECF system, which will automatically serve and send notification of such filing to all registered attorneys of record.

/s/ Michelle Yeary